Retatrutide, a groundbreaking dual-acting glucose-responsive incretin mimetic, represents a significant progression in peptide treatments for the handling of type 2 diabetes and, increasingly, excess adiposity. Unlike many existing medicinal interventions, retatrutide merges the actions of a GLP-1 receptor agonist and a GIP receptor stimulant, offe